<DOC>
	<DOCNO>NCT00742404</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth block blood flow tumor . Giving bortezomib together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give doxorubicin hydrochloride liposome together bortezomib dexamethasone work treat patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome , Bortezomib , Dexamethasone Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine response rate ( i.e. , complete response , good partial response , partial response , minimal response ) patient newly diagnose multiple myeloma treat pegylated liposomal doxorubicin hydrochloride , bortezomib , dexamethasone . Secondary - To assess safety tolerability regimen patient . - To determine time disease progression , time response , duration response , progression-free survival , overall survival patient treat regimen . OUTLINE : Patients receive pegylated liposomal doxorubicin hydrochloride IV 30-90 minute , dexamethasone IV , bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . Blood urine sample collect baseline periodically study M-protein analysis electrophoresis immunofixation . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma base follow criterion : Major criterion Plasmacytomas tissue biopsy ( 1 ) Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) ( 2 ) Monoclonal immunoglobulin spike serum electrophoresis IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL kappa lambda light chain excretion &gt; 1 g/day 24hour urine protein electrophoresis ( 3 ) Minor criteria Bone marrow plasmacytosis ( 10 % 30 % plasma cell ) ( ) Monoclonal immunoglobulin present less magnitude give major criterion ( b ) Lytic bone lesion ( c ) Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL ( ) Meets 1 follow set diagnostic criterion : Any two major criterion Major criterion 1 minor criterion b , c , Major criterion 3 minor criterion c Minor criterion , b , c , OR , b , Measurable disease , define monoclonal immunoglobulin spike serum electrophoresis ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike ≥ 200 mg/24 hour , evidence lytic bone disease No nonmeasurable disease ( i.e. , nonsecretory oligosecretory multiple myeloma ) Symptomatic , newly diagnose , previously untreated multiple myeloma No POEMS syndrome ( i.e. , plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein [ Mprotein ] , skin change ) No plasma cell leukemia PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 3 month ANC ≥ 1,500/mm^³ ( ≥ 1,000/mm^³ bone marrow extensively infiltrate ) Platelet count ≥ 75,000/mm^³ ( ≥ 50,000/mm^³ bone marrow extensively infiltrate ) Hemoglobin ≥ 8.0 g/dL AST ALT ≤ 3.0 time upper limit normal ( ULN ) Serum bilirubin ≤ 2.0 time ULN Creatinine clearance ≥ 30 mL/min OR creatinine &gt; 10 mL/min &lt; 30 mL/min patient significant myelomatous involvement kidney Serum potassium ≥ low limit normal ( LLN ) Serum sodium ≥ LLN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No peripheral neuropathy ≥ grade 2 within past 14 day No impaired cardiac function clinically significant cardiac disease , include one following : Myocardial infarction within past 6 month New York Heart Association class IIIV heart failure Uncontrolled angina Clinically significant pericardial disease Severe uncontrolled ventricular arrhythmias LVEF normal ECHO MUGA scan ECG evidence acute ischemia active conduction system abnormalities Screening ECG abnormality must document investigator medically relevant No severe hypercalcemia ( i.e. , serum calcium ≥ 14 mg/dL [ 3.5 mmol/L ] ) No poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could preclude study treatment No known HIV positivity hepatitis B C positivity Baseline test HIV hepatitis B C require No history allergic reaction attributable compound similar chemical biological composition doxorubicin , bortezomib , boron , mannitol PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior concurrent antimyeloma therapy except steroid Prior prednisone ≤ 4 day total 400 mg ( equivalent potency another steroid ) allow No concurrent corticosteroid ( ≥ 10 mg prednisone/day equivalent ) dexamethasone More 4 week since prior major surgery recover Prior kyphoplasty oncotherapeutic drug allow investigator 's discretion More 4 week since prior immunotherapy , antibody therapy , radiotherapy More 14 day since prior concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>